bioRxiv Science⌕ Search

Biology subjects

Croy, I.

Publications and source records attributed to Croy, I..

5 recordsLinked to original sources

A normative reference for large-scale human brain dynamics across the lifespan

Human brain function emerges from dynamic reconfigurations of large-scale neural networks. While population-level reference charts have transformed the study of static brain structure and connectivity, an equivalent normative framework for intrinsic brain dynamics has been lacking. This gap has limited our ability to characterize individual variability, development, ageing, and mental health conditions at scale. Here, we establish a population-level normative reference for large-scale human brain dynamics using resting-state fMRI data from more than 10,000 individuals spanning the lifespan and 91 scanning sites. We derive a compact set of recurring brain-state configurations that are reproducible across scanners and acquisition paradigms and that generalize to previously unseen cohorts. Anchoring these dynamic states to normative lifespan models enables the quantification of individual deviations relative to population reference distributions. We show that intrinsic brain dynamics undergo systematic reorganization across development and ageing, with pronounced changes before early adulthood and more gradual modulation thereafter. Applying this framework across multiple mental health conditions reveals disorder-specific and highly heterogeneous deviations in brain dynamics that are not captured by static neuroimaging measures. Robust transfer to independent cohorts and longitudinal analyses demonstrate that normative brain dynamics can be reliably assessed out of distribution. These results delineate a population-scale dynamic architecture of the human brain and extend normative brain mapping from static phenotypes to the temporal domain, providing a reference framework for studying brain function across the lifespan in health and disease.

neuroscience↗

Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma

ObjectiveClear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, but up to 30% of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy for low-stage CCOC (FIGO stage IA-IC1) remains uncertain. This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort. MethodsUsing the Edinburgh Ovarian Cancer Database, we identified 85 CCOC cases. Targeted DNA sequencing assessed genomic alterations and tumour immune infiltration was evaluated using CD3 and CD8 immunohistochemistry on tissue microarrays. Tumours were stratified by stage (IA-IC1, IC2-II, III-IV), and both univariate and multivariate analysis applied for progression-free survival (PFS) included stage, age, genomic features, and immune markers. ResultsCommon genomic alterations included ARID1A (49%) and PIK3CA (42%) mutations, PIK3-AKT pathway perturbations (60%), and mismatch repair-related mutational signatures (25.9%). Genomic and molecular features were not significantly associated with tumour stage; however, low-stage tumours (IA-IC1) were enriched in CD3+ (40% cases) and CD8+ (29% cases) tumour-infiltrating lymphocytes (TILs) compared to higher-stage tumours (IC2-II: 13%/7%; III-IV: 9%/0% cases). In univariate analysis, low CD3+ TIL levels were significantly associated with reduced progression-free survival (HR = 4.4, P = 0.042, 95% CI 1.1-18). ARID1A wild-type status was linked to poorer PFS but only in low-stage tumours HR = 7.2, P = 0.088; 95% CI 0.74-72). Notably, the combination of ARID1A wild-type status and CD3+ depletion identified a high-risk subgroup among low-stage CCOC cases (HR = 11.7, P = 0.050; 95% CI 1-138), highlighting potential as a composite risk marker set. ConclusionsCombined ARID1A mutation and low CD3+ve TIL levels are suggestive of higher recurrence risk in low-stage CCOC patients. These findings support further investigation of targeted therapies or immune checkpoint inhibitors in larger CCOC cohorts. HighlightsO_LIWe report a well-characterized CCOC cohort with rich clinical, genomic and molecular data. C_LIO_LICommon mutations included ARID1A (49%) and PIK3CA (42%), with MSI in 9%, showing no significant enrichment across tumour stages. C_LIO_LILow-stage CCOC has higher levels of CD3+ & CD8+ tumour infiltrating leukocytes than in advanced-stage disease. C_LIO_LIARID1A wild-type tumours with CD3+ TIL depletion represent a high-risk subgroup of low-stage CCOC. C_LIO_LIFindings support further study and highlight potential markers for recurrence risk. C_LI

cancer biology↗

Relationship as resource or burden? Associations of attachment style, relationship quality and dyadic coping with acute psychosocial stress in the presence of the romantic partner

Stress is a wide-spread phenomenon and associated with various detrimental health effects. A significant resource for stress buffering is social support. How social support is perceived, however, depends on a multitude of individual and interindividual factors. This study aimed to explore the stress-reducing properties of relationship-inherent variables. We investigated the association of attachment style, relationship quality and dyadic coping, with subjective and physiological stress responses to a psychosocial laboratory stressor in romantic partners. Seventy-nine couples participated, with one partner ("target") undergoing the Trier Social Stress Test and the other ("observer") observing the situation. Besides examining the role of targets relationship variables, we also assessed the link between observers relationship variables and targets stress reactivity. We found that both targets and observers insecure-avoidant attachment scores were associated with targets stress reactivity. In detail, while targets insecure-avoidant attachment scores were negatively associated with targets subjective stress experience, observers insecure-avoidant attachment scores were positively associated with targets heart rate reactivity. Further, higher insecure-avoidant attachment scores linked to lower psycho-endocrine covariance, i.e., a lower accordance between self-reported and cortisol stress responding. On the one hand, these data may suggest that under stress, insecure-avoidantly attached individuals suppress their experience of stress to preserve a sense of independence as part of their deactivating attachment strategy. The presence of an insecure-avoidantly attached partner during a stressful experience, on the other hand, seems to be a stressor rather than a source of support. Long-term, an insecure-avoidantly attached partner may negatively impact an individuals stress-related health and wellbeing. Highlights- In a situation in which one romantic partner experienced stress ("target") while being ob- served by their partner ("observer"), insecure-avoidant attachment of both predicted the tar- gets stress response - Targets insecure-avoidant attachment was associated with lower subjective stress in the tar- gets - Observers insecure-avoidant attachment was related to higher heart rate reactivity in the targets - Insecure-avoidant attachment was associated with lower psycho-endocrine covariance

neuroscience↗

Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer

Deciphering the structural variation across tumour genomes is crucial to determine the events driving tumour progression and better understand tumour adaptation and evolution. High grade serous ovarian cancer (HGSOC) is an exemplar tumour type showing extreme, but poorly characterised structural diversity. We comprehensively describe the mutational landscape driving HGSOC, exploiting a large (N=324), deeply whole genome sequenced dataset. We reveal two divergent evolutionary trajectories, affecting patient survival and involving differing genomic environments. One involves homologous recombination repair deficiency (HRD) while the other is dominated by whole genome duplication (WGD) with frequent chromothripsis, breakage-fusion-bridges and extra-chromosomal DNA. These trajectories contribute to structural variation hotspots, containing novel candidate driver genes with significantly altered expression. While structural variation predominantly drives tumorigenesis, we also find high mtDNA mutation loads associated with shorter patient survival, and acting in combination with alterations in the nuclear genome to impact prognosis and suggesting new strategies for patient stratification.

cancer biology↗

Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma

Around half of high grade serous ovarian carcinomas (HGSOC) show homologous recombination repair deficiency (HRD), often caused by germline or somatic single nucleotide variant (SNV) mutations or small indels disrupting BRCA1/2. We have uniformly processed the largest collection of whole genome sequencing (WGS) data from HGSOC samples to date (N=205), comprehensively characterising the somatic mutational landscape, and expression at the BRCA1/2 loci. We discover that large structural variants (SV) are a frequent but unappreciated source of BRCA1/2 disruption in these tumours. Somatic structural variation at these loci is dominated by multi-megabase deletions that span the entirety of BRCA1 (median = 4.9Mb) or BRCA2 (median = 6.2Mb), independently affecting a substantial proportion of patients (16%) in addition to those affected by damaging germline or somatic short variants, within the BRCA1/2 coding sequences (24%). In common with previous studies, we show that the presence of damaging somatic SNVs or short indels in BRCA1 (OR=10, 95% CI 1.8-103, p=0.002, adj p=0.027 and BRCA2 (OR=17, 95% CI 2.1-816), p=0.002, adj.p=0.021) was found to influence HRD. For the first time we also study the compound effect of SV and SNV or short indel mutations at both loci, demonstrating that SVs often contribute to compound deficiencies involving SNVs or indels, with large somatic deletions contributing to these compound deficiencies in 15/205 (7%) of samples. Notably the strongest risk of HRD (OR=19 (2.4-896), p=6.6x10-3, adj P=8.5x10-3) is generated by combined large deletions at BRCA1 and BRCA2 in the absence of SNVs or indels, affecting 3% of patients. Overall, we show that HRD is a complex phenotype in HGSOC tumours, affected by the patterns of shorter variants such as SNVs and indels, SVs, methylation and expression seen at multiple loci, and we construct a successful (ROC AUC = 0.75) predictive model of HRD using such variables. In addition, HRD impacts patient survival when conferred by mechanisms other than through the well-understood short variants at BRCA1/2, currently exploited in the clinic. These results alter our understanding of the mutational landscape at the BRCA1/2 loci in highly rearranged tumours, and increase the number of patients predicted to benefit from therapies exploiting HRD in tumours such as PARP inhibition.

cancer biology↗